Of the 184 patients treated with fluoropyrimidine and oxaliplatin, 138 received bevacizumab. The majority of patients, 93%, received FOLFOX chemotherapy, with the remainder receiving CAPOX. There were no statistical differences between the two groups (Table 1). In particular, the cumulative oxaliplatin exposure was similar between the bevacizumab- and nonbevacizumab-treated cohorts. The median time to splenic enlargement of 30% or greater was longer in the bevacizumab cohort (7.6 vs 5.5 months, P = .02). The six-month cumulative incidence rates of splenic enlargement of 30% or greater were 63% in the nonbevacizumab cohort and 44% in the bevacizumab cohort (P = .08) (Supplementary Figure 1A, available online). There was no difference when using a higher threshold of 50% or greater (P = .82). The six-month cumulative incidence of thrombocytopenia (platelet count < 100 000/mm³) did not differ between the nonbevacizumab cohort and the bevacizumab cohort (17% vs 17%, P = .69) (Supplementary Figure 1B, available online). Due to the low event rate, an exploratory analysis using a platelet count threshold below the lower limit of normal (<150 000/mm³) was conducted, and the six-month cumulative incidence was 70% in the nonbevacizumab cohort and 56% in the bevacizumab cohort (P = .04) (Supplementary Figure 1C, available online). When comparing patients with and without splenic enlargement of 30% or greater, the rate of thrombocytopenia (platelet count < 100 000/mm³) at three months was 40% vs 16%, respectively (P < .001). In the Cox model regarding the time to splenic enlargement, where propensity score was used to adjust for covariate bias and difference, an estimated 1.61-fold reduction in the rate of splenomegaly was observed with the addition of bevacizumab (hazard ratio [HR] = 0.62, 95% confidence interval [CI] = 0.38 to 1.02, P = .06). Similarly, the use of bevacizumab was associated with an estimated 1.59-fold reduction in the rate of thrombocytopenia (platelet count < 150 000/mm³; HR = 0.63, 95% confidence interval [CI] = 0.40 to 1.00, P = .05) (Supplementary Table 1, available online).